不同粒径石杉碱甲纳米粒的制备及其在小鼠体内分布特性研究

来源 :解放军药学学报 | 被引量 : 0次 | 上传用户:china_huohou
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的研究不同粒径石杉碱甲纳米粒在小鼠体内的分布情况。方法以聚乳酸-羟基乙酸(PLGA)为载体材料,采用乳化溶剂挥发法制备不同粒径的石杉碱甲纳米粒;采用小动物活体成像技术研究不同粒径纳米粒在小鼠体内的分布情况。结果制备了粒径从43.1 nm到316 nm的石杉碱甲纳米粒,载药量从0.11%到2.42%。不同粒径纳米粒在小鼠体内的动态分布研究表明,粒径为50 nm左右的纳米粒可以分布于全身各个器官,并能透过血脑屏障,且能起到缓释的效果;粒径为100~300 nm左右的纳米粒主要分布于肝脏,且较难透过血脑屏障。结论该研究为进一步开发高效、低毒的石杉碱甲新型制剂提供了重要参考。 Objective To study the distribution of huperzine A nanoparticles with different particle sizes in mice. Methods Polyglutamic acid-glycolic acid (PLGA) was used as a carrier material to prepare huperzine A nanoparticles with different particle sizes by emulsion solvent evaporation method. The distribution of nanoparticles with different particle sizes in mice was studied by live animal imaging . Results Huperzine A nanoparticles with diameters ranging from 43.1 nm to 316 nm were prepared with drug loading ranging from 0.11% to 2.42%. The study on the dynamic distribution of nanoparticles with different particle size in mice showed that the nanoparticles with particle size of about 50 nm can be distributed in various organs of the body and can penetrate the blood-brain barrier, and can play a sustained release effect. The particle size Nanoparticles of 100-300 nm are mainly distributed in the liver and more difficult to penetrate the blood-brain barrier. Conclusion The study provides an important reference for the further development of a new type of huperzine A with high efficiency and low toxicity.
其他文献
1临床资料rn患者,男,51岁,主因脑出血术后12 d,发热4d入院,头部、胸部CT提示:左侧基底节脑出血入脑室系统术后,肺部感染.既往高血压病10年,自服药物,具体不详,糖尿病4年,未正
期刊
@@